Are you aware
of the continuing risk of septic transfusion reactions?

Patient safety comes first.
Take no chances with blood.

If you are not ensuring complete elimination of bacteria, there will always be the risk of transfusion transmitted bacterial infection through platelet components and the chance of a septic transfusion reaction.

At CERUS, we leave nothing to chance. Our pathogen inactivation technology presents the best possible option of going for zero septic transfusion reactions in patients.1

Given that transfusion transmitted bacterial infection and septic transfusion reaction remain the principle causes of mortality related to transfusion2, we thought it is our duty to address this blood safety risk in greater depth.

We will bring you up to date with the latest, most relevant insights in a series of short educational webinars hosted by experts to cover three key subjects:

Webinar 1

Bacterial contaminations. Transfusion transmitted bacterial infection and septic transfusion reaction

Webinar 2

Options for bacterial risk control. Merits and pitfalls

Webinar 3

How to bring bacterial risk control strategies within financial reach

We start on January 27th from 3.00 to 4.15 pm (CET) with our first webinar discussing:


Bacterial contamination rates in platelet components


Rationale on why bacterial contaminations don’t always cause clinical sepsis


Why septic transfusion reactions often remain invisible and underreported

See full educational programme details

Please partner with us in 2021 to help reduce the number of avoidable septic transfusion reactions and fatalities in patients.

Take no chances with blood. Register now for Webinar One.

Register noW

1. Richard J. Benjamin, Thomas Braschler, Tina Weingand. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems. Transfusion2017;57;2946-2957.

2. United States Government. Food & Drug Administration (FDA). Fatalities reported to FDA following blood collection and transfusion: annual summary for FY2017.

Use of INTERCEPT™ Plasma or Platelets is contraindicated in patients with a history of allergic response to amotosalen or psoralens.
Consult instructions for use for indications, contraindications, warnings, and precautions.
Copyright © 2020 Cerus Europe BV, All rights reserved.
INTERCEPT Blood System and INTERCEPT are trademarks of Cerus Corporation.
INTERCEPT Blood System is not approved for sale in certain countries.

MKT-EN 00477-01, v1.0